530-75-6

Basic information

• Product Name: ACETYLSALICYLSALICYLIC ACID
• Synonyms: o-(o-Acetoxybenzoyloxy)benzoic acid;2-(Ace;Aspirin EP IMpurity D;Aspirin IMpurity D;2-((2-Acetoxybenzoyl)oxy)benzoic acid,95+%;DIPLOSALSALATE;(Acetysalicylsalicyclic acid);Acetylsalicylic Acid IMpurity D (Aspirin IMpurity D)
• CAS NO: 530-75-6
• Molecular Formula: C₁₆H₁₂O₆
• Molecular Weight: 300.26
• EINECS: 208-493-6
• Product Categories: Chemical Impurities;Impurities;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 530-75-6.mol

Chemical Properties

• Melting Point: 153-160 °C
• Boiling Point: 361.5°C (rough estimate)
• Flash Point: 203.9 °C
• Appearance: White to almost white fine crystalline powder
• Density: 1.346
• Vapor Pressure: 1.7E-12mmHg at 25°C
• Refractive Index: 1.4600 (estimate)
• Storage Temp.: Sealed in dry,Room Temperature
• Solubility: Chloroform (Sparingly), DMSO (Sparingly), Methanol (Slightly)
• PKA: 2.94±0.36(Predicted)
• Water Solubility: 20mg/L(21 oC)
• CAS DataBase Reference: ACETYLSALICYLSALICYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: ACETYLSALICYLSALICYLIC ACID(530-75-6)
• EPA Substance Registry System: ACETYLSALICYLSALICYLIC ACID(530-75-6)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 24/25
• Hazardous Substances Data: 530-75-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Acetylsalicylsalicylic Acid is used as an analgesic for the relief of mild to moderate pain, such as headaches, muscle aches, and joint pain. It is also used as an antipyretic to reduce fever and inflammation.
Used in Cardiovascular Applications:
Acetylsalicylsalicylic Acid is used as an antiplatelet agent to prevent blood clot formation, which can help in the treatment and prevention of heart attacks, strokes, and other cardiovascular events.
Used in Antithrombotic Applications:
In the medical field, Acetylsalicylsalicylic Acid is used as an antithrombotic agent to inhibit platelet aggregation and reduce the risk of thrombosis, which can lead to life-threatening conditions such as deep vein thrombosis and pulmonary embolism.
Used in Acetylsalicylic Acid Impurity C:
Acetylsalicylsalicylic Acid is used in the production of Acetylsalicylic Acid Impurity C, which is a byproduct in the synthesis of Aspirin. This impurity is important for quality control and safety assessments in the pharmaceutical industry.

Purification Methods

Crystallise the analgesic from dilute AcOH or EtOH (m 161-162o), MeOH (m 165-168o), and *C6H6/EtOH (m 163-165o). Its solubilities in boiling Et2O, *C6H6 and EtOH are 1.4%, 2.2% and 33%, respectively. [Baker et al. J Chem Soc 201 1951, Garrett et al. J Am Pharm Soc 48 684 1959, Beilstein 10 I 41, 10 II 54, 10 IV 165.]

InChI:InChI=1/C16H12O6/c1-10(17)21-14-9-5-3-7-12(14)16(20)22-13-8-4-2-6-11(13)15(18)19/h2-9H,1H3,(H,18,19)/p-1

Upstream product

• 110-86-1 pyridine 
• 1466-82-6 aspirin anhydride 
• 36335-42-9 (2-acetoxy-benzoyl)-carbonic acid ethyl ester 
• 50-78-2 aspirin 
• 64-17-5 ethanol 
• 54-21-7 sodium salicylate 
• 552-94-3 2-hydroxy-benzoic acid, 2-carboxyphenyl ester 
• 121-69-7 N,N-dimethyl-aniline 
• 69-72-7 salicylic acid 
• 67-64-1 acetone 
• 5538-51-2 O-acetylsalicyloyl chloride 
• 108-24-7 acetic anhydride 

Downstream Products

• 98281-97-1 [2-(2-acetoxy-benzoyloxy)-benzoic acid ]-acetic acid-anhydride 
• 552-94-3 2-hydroxy-benzoic acid, 2-carboxyphenyl ester 
• 1003572-58-4 2-(chlorocarbonyl)phenyl 2-(acetyloxy)benzoate 
• 124118-53-2 2-(2-acetoxy-benzoyloxy)-benzoic acid-anhydride 
• 50-78-2 aspirin 
• 85531-21-1 2-(2-acetoxy-benzoyloxy)-benzoic acid methyl ester 
• 6034-63-5 2-(2-acetoxy-benzoyloxy)-benzoic acid amide 

Relevant articles and documents

COMPOSITIONS FOR THE TREATMENT OF DIABETES AND PRE-DIABETES

The invention relates to the compositions of formula I or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprises a salt of metformin and the methods for treating or preventing metabolic syndrome, prediabetes and diabetes may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of diabetes mellitus, obesity, lipid disorders, hypertriglyceridemia, hyperglycemia, hyperinsulinemia and insulin resistance.

COMPOSITIONS AND METHODS FOR THE TREATMENT OF DIABETES AND PRE-DIABETES

The invention relates to the compositions of formula I or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprises a salt of metformin and the methods for treating or preventing metabolic syndrome, prediabetes and diabetes may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of diabetes mellitus, obesity, lipid disorders, hypertriglyceridemia, hyperglycemia, hyperinsulinemia and insulin resistance.

Solid-state stability of aspirin in the presence of excipients: Kinetic interpretation, modeling, and prediction

Salicylsalicylic acid and acetylsalicylsalicylic acid were identified as decomposition products of aspirin when mixtures of the drug, with magnesium stearate, were stored in the solid state at 60° and 75% relative humidity. The effect of increasing the concentration of magnesium stearate and the addition of other alkali stearates on the rate of decomposition of aspirin were studied. The validity of the theory that pH changes induced by the alkali stearates account for the catalytic effect of the lubricants on the decomposition was tested. The changes observed were modeled and the mechanism involved elucidated. The potential use of the melting points of aspirin mixtures in predicting the stability of the drug in such drug-excipient mixtures is demonstrated.